Welcome to the DZIF -

the German Center for Infection Research

Information on SARS-CoV-2

Visit page

Research Areas

DZIF is doing research in nine areas:

Gastrointestinal Infections

Hepatitis

HIV

Infections of the immunocompromised Host

Healthcare-associated and Antibiotic-resistant bacterial Infections

Malaria

Emerging Infections

Novel Antibiotics

Tuberculosis

News

News and Press Releases.

Dr. Silvia Portugal im Heidelberger Labor
© Universitätsklinikum Heidelberg

Malaria: Playing hide and seek in the dry season

Christoph Lange vor Röntgenbildern
© Forschungszentrum Borstel

Milestone in the prevention of tuberculosis

Based on data involving more than 80,000 patients, an international research group has developed a programme that can predict the individual risk of tuberculosis. The results of this work were
Impfung
© Hyttalo Souza

First volunteers receive COVID-19 vaccine in phase I clinical trial

The vaccine trial is on track. Last Friday, on 9 October, the first test subject was injected with the vaccine MVA-SARS-2-S against COVID-19. A total of six volunteers received the vector vaccine to
Resistenzgene nachweisen
© JLU Gießen

Learning lessons from the coronavirus pandemic on containing other infections

Healthcare-associated infections have been growing continuously for years, resulting in hundreds of thousands of avoidable deaths each year. The main culprit is bacteria that have become resistant to
idt Abfüllanlage
© Hartmut Bösener/IDT Biologika

First clinical trial of DZIF vaccine against COVID-19 gets go-ahead

The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, today approved the clinical trial of the MVA-SARS-2-S vaccine against COVID-19. The vector vaccine was developed by
All news

Up-to-date information and behaviour rules

Coronavirus info

European Centre for Disease Prevention and Control (ECDC):
https://www.ecdc.europa.eu/en/novel-coronavirus-china
World Health Organization (WHO):
https://www.who.int/emergencies/diseases/novel-coronavirus-2019
German Federal Government:
https://www.bundesregierung.de/breg-en/search/ausbreitung-coronavirus-1…

Coronavirus

Always up-to-date

Sign up for our quarterly newsletter and our press releases and stay up to date.

Select mailing lists

Follow us on:

The DZIF Media Centre

The DZIF in Videos, Pictures and Print.

Pipetting aid
© Fabian Grein/DZIF
image jpeg (1.16 MB)

Pipetting aid

jpeg (1.16 MB)
Find Media Content

Research in Focus

Hamburg - Lübeck - Borstel - Riems

Clinical Tuberculosis Centre

The Clinical Tuberculosis Centre provides the expertise and infrastructure for the optimisation, prevention, diagnosis and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Centre include coordinating clinical research activities involving the DZIF TB cohort. This cohort includes [...]

Read more
Hannover - Braunschweig | Heidelberg | München | Tübingen

Transplant Cohort

Medical data and biological samples obtained from transplant patients are collected and managed across Germany with the help of the DZIF Transplant Cohort. The data and samples form the basis of scientific studies which investigate the connections between numerous factors influencing an organ’s susceptibility to infection and organ function. 

In [...]

Read more
Tübingen

New strategies for specific eradication of Staphylococcus aureus

In this project, the scientists develop genetically engineered phage lysins and specific bacteriocins for the elimination of hospital germs such as Staphylococcus aureus, they clarify mechanisms of potential resistance mechanisms, and they analyse whether broad-spectrum or specifically acting agents have a more effective and lasting effect on colonization by S [...]

Read more
Hannover - Braunschweig

Preclinical development of Amidochelocardins

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of chelocardin, this antibiotic substance was identified several [...]

Read more

Our Partner Sites

München Tübingen Heidelberg Giessen – Marburg – Langen Bonn – Köln Hannover – Braunschweig Hamburg – Lübeck Borstel – Riems
42
Databases- & Biobanks 2019